Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France

Observational Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Treated With Dupilumab in France

This is a multicentre, non-interventional, single arm study that aims to describe the treatment patterns in France: patients' characteristics, disease characteristics, prior treatments for Severe chronic rhinosinusitis with nasal polyposis and treatment prescription modalities. As well as to assess the clinical outcome after initiation of dupilumab (Dupixent®) and safety of the product during the two years of treatment

Inclusion Criteria:

• Patient aged >= 18 years old at the time of the initiation of the treatment with dupilumab (Dupixent®).
• Decision to initiate Dupixent® prior to inclusion in the study, initiation of Dupixent® for severe Chronic rhinosinusitis with nasal polyposis (CRSwNP) maximum 3 months before inclusion.
• Informed consent and willingness to participate.

Exclusion Criteria:

• Conditions or legal situations resulting in impossibility to consent or impacting the interpretation of the results.
• Patient participating in an interventional clinical trial with experimental product at inclusion.